Discussion of Lot-to-Lot Variability for C19 Injections and Relationship to Product vs Age

Team Enigma were asked to respond to analyses that claim there is no product related heterogeneity in C19 Injections, and that all variability in lot-to-lot adverse events, deaths and disabilities can be explained by relationship to age. We believe it is inappropriate to assume that there is no underlying product heterogeneity, and we explain why in a longish talk (55 min). We believe that age of vaccine recipients has definite impact on mortality, but does not fully explain the vast variability patterns that we see. We also explain that one variable, such as age, is insufficient to understand the complex toxic effects. Our guest Dr. Mikael Nordfors from Denmark asks questions.